Gene Patches: Classified As Drugs
Presenter: Neal Howard
Guest: Dr. Stephen Shrewsbury
Guest Bio: Dr. Shrewsbury was most recently Senior Vice President, Preclinical & Clinical Development and Chief Medical Officer of AVI BioPharma (now Sarepta Therapeutics). From 2005 until 2009, he held similar roles at Adamas Pharmaceuticals and MAP Pharmaceuticals. While at MAP, Dr. Shrewsbury lead four inhaled drug programs and took two lead candidates (in asthma and migraine) from preclinical stage to Phase III in 18 months. Prior to his experience in biotechnology, Dr. Shrewsbury spent 10 years with Glaxo and Chiron launching notable respiratory programs such as Seretide in Europe and Flovent and Advair in the US. Dr. Shrewsbury received his medical degree from the University of Liverpool, UK and spent 13 years working in the UK National Health Service before entering the pharmaceutical industry.
Segment Overview
Dr. Stephen Shrewsbury discusses why gene patches are classified as drugs and tested in the same way as conventional drugs.
Transcription
Health Professional Radio
Neal Howard: Hello. You’re listening to Health Professional Radio. I’m your host Neal Howard. Thank you so much for hanging with us this afternoon. It’s our pleasure to have in studio today, Dr Stephen Shrewsbury. He’s returning and we’re going to talk a little bit more today about our DNA. He’s the author of Defy Your DNA. It’s not a negative defiance. It’s actually a positive thing in that we’re trying to alleviate or eliminate some of the rare diseases that afflict us, many of us on a daily basis.
Maybe gene patch therapy can be the next first line of defence when it comes to things like muscular dystrophy or some diseases of the heart or even weight loss by actually changing the way our DNA speaks to our bodies. How are you doing, Steve?
Want to continue reading? Please log-in or register to see the Full Transcript.
